1. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia
- Author
-
Cynthia Timmers, Kerry A. Rogers, Jeffrey A. Jones, Nicole Grieselhuber, Leslie A. Andritsos, Julie W. Reeser, Sameek Roychowdhury, Aharon G. Freud, Christopher C. Oakes, Mirela Anghelina, Dan Jones, Gerard Lozanski, David M. Lucas, James S. Blachly, Michael R. Grever, and Katie Williams
- Subjects
0301 basic medicine ,Trametinib ,Cancer Research ,Mutation ,Chemotherapy ,Chemistry ,medicine.medical_treatment ,Mutant ,Hematology ,medicine.disease ,medicine.disease_cause ,Uncommon disorder ,Article ,03 medical and health sciences ,Leukemia ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,MAP2K1 ,medicine ,Cancer research ,Hairy cell leukemia - Abstract
Variant hairy cell leukemia (vHCL) is an uncommon disorder accounting for 10% of all HCL cases [1]. The difference in therapeutic response to chemotherapy between patients with classic HCL (cHCL) a...
- Published
- 2017